Shire acquisitions, on the record

Word for word“On January 22, 2016 Shire also completed the acquisition of all the outstanding share capital of Dyax for a total upfront cash consideration of approximately $5.9 billion and a further approximately $0.6 billion in cash consideration contingent upon the approval of DX-2930 for the prophylactic treatment of HAE.” 10-K for 2015

Word for word“On February 21, 2015, Shire completed the acquisition of NPS Pharma for a total cash consideration of approximately $5.2 billion.” 10-K for 2015

Word for word“Finally, on January 11, 2016 Shire announced a combination with Baxalta Incorporated had been agreed by both Boards.” 10-K for 2015

Word for word“With the acquisition of Foresight on July 30, 2015, Shire acquired global rights to SHP640, a therapy in late-stage development for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye.” 10-K for 2015

Word for word“With the Meritage acquisition, Shire acquired the global rights to Meritage Pharma’s compound, OBS, for the treatment of adolescents and adults with EoE, a rare, chronic inflammatory GI disease.” 10-K for 2015

Word for word“On July 4, 2014 Shire completed its acquisition of Fibrotech Therapeutics Pty Ltd. (Fibrotech”), an Australian biopharmaceutical company developing a new class of orally available drugs with a novel mechanism of action which has the potential to address both the inflammatory and fibrotic components of disease processes.” 10-K for 2015

Word for word“SHP625 for the treatment of cholestatic liver disease SHP625 was acquired as part of the recent acquisition of Lumena Pharmaceuticals, Inc. (“Lumena”) Shire is currently conducting Phase 2 studies in the following indications: Alagille Syndrome (“ALGS”), Progressive Familial Intrahepatic Cholestasis (“PFIC”), and Primary Sclerosing Cholangitis (“PSC”).” 10-K for 2015

Word for word“Following the acquisition of NPS Pharma in February 2015, Shire receives royalties arising from NPS Pharma's collaborations with Amgen and Kyowa Hakko Kirin.” 10-K for 2016

Word for word“In July 2015, the Company acquired the ONCASPAR (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A.” 10-K for 2016

Word for word“In October 2016, Shire decided to divest the facility in Krems, Austria.” 10-K for 2016